Purpose, strategy and culture

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.

We aim to positively impact the health of 2.5 billion people over the next 10 years. Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance.

We are a company where outstanding people can thrive.

Our strategy

We are a focused biopharma company. We prevent and treat disease with specialty medicines, vaccines and general medicines. We focus on the science of the immune system and advanced technologies, investing in four core therapeutic areas - respiratory, immunology and inflammation; oncology; HIV and infectious diseases – to impact health at scale. Our Ahead Together strategy means intervening early to prevent and change the course of disease, helping to protect people and support healthcare systems.

Our R&D approach

Partner with GSK

Our portfolio

Specialty medicines

Specialty medicines are prescribed by specialist healthcare practitioners. Our portfolio of specialty medicines prevents and treats diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer.

Vaccines

Our portfolio of more than 20 marketed vaccines is one of the broadest in the industry. We deliver more than 1 million doses of our vaccines every day. Our vaccines portfolio targets infectious diseases from birth throughout adulthood.

escherichia-coli-e-coli-bacteria-science-image-rgb

General medicines

General medicines are usually prescribed in primary care or community settings by general healthcare practitioners. General medicines include inhalers for asthma and COPD to antibiotics. Every day, our general medicines make life better for millions of people all over the world.

How we prevent and treat diseases

Our therapeutic areas

Respiratory, immunology and inflammation

We have a deep understanding of the underlying drivers of disease in different groups of patients with conditions like asthma and COPD. Our ambition is to redefine the future of respiratory medicine with a broad portfolio of next-generation treatments that work in distinct ways to help as many people as possible.

We’re building on our decades of knowledge in inflammatory mechanisms to target fibrotic lung, liver and kidney disease.

Oncology

Our ambition is to help increase overall quality of life, maximise survival and change the course of disease, expanding from our current focus on blood and gynaecologic cancers into lung and gastrointestinal cancers, as well as other solid tumours.

Our research uses precision medicine-based technology to match the right treatment to the right patient.

HIV

For nearly four decades, we’ve worked to improve the lives of people living with HIV or those who could benefit from prevention and protection from injection.

Our work in HIV is led by ViiV Healthcare, which we majority-own, with Pfizer and Shionogi as shareholders. ViiV Healthcare is the only company exclusively dedicated to treating and preventing HIV with an ambition to end the HIV epidemic.

Infectious diseases

We intend to have a positive impact on the lives of more than 2.5 billion people by the end of the decade and a significant proportion of this will be through our work in infectious diseases. Our portfolio here is the broadest in the industry.

Our priorities include seasonal infections, chronic infections, common childhood diseases and rarer but critical conditions like meningitis. We also focus on bacterial infections where resistance is creating an urgent need for new treatments.

Our long-term priorities

By combining our understanding of the science of the immune system with cutting-edge technology, we can discover and develop new medicines and vaccines with the potential to transform people’s lives. Rapid advances in science and technology are unlocking new opportunities to prevent and treat disease. Our broad portfolio and pipeline continues to strengthen, with key milestones across our core therapeutic areas in 2024. To complement our in-house R&D, we partner with the world’s best minds to enable access to novel science and technology.

R&D approach

Assets in the pipeline
71
Positive pivotal data read-outs in 2024
13
Filings/approvals in 2024
23

How we innovate

We’re confident in our future. Our bold ambitions for patients are reflected in new commitments to growth and a significant step-change in delivery over the next five years. This means more GSK vaccines and medicines, including innovative new products, will reach more people who need them than ever before.

Investors

Creating value for patients, shareholders, society

Packs of medicines and doses of vaccines delivered in 2024
2.1bn
Per share dividend in 2024
61p

Our latest performance figures

Why invest in GSK?

Being a responsible business is an integral part of our strategy. We apply our strengths and take action in the areas that can most positively impact patients, society and our people over the long-term. This includes pricing and access, sustainability, global health and health security, inclusion, product governance and operating standards.

Our Responsibility

Our Global Responsibility

In India, we support our people to help deliver on our ambition for patients, address select national health priorities and widen access to medicines to create value for our stakeholders and society at large.

In India, GSK has always been at the forefront of science and harnesses the power of talent, technology and research to improve the quality of human life. To deliver on our purpose of getting ahead of disease, we rely on our outstanding people, and work hard to create a facilitative environment where they can thrive and achieve exceptional outcomes.

Our culture

Culture at GSK is something we all own. It powers our purpose, drives delivery of our strategy and helps make GSK a place where people can thrive. Our culture of being ambitious for patients, accountable for impact and doing the right thing are the foundations for how, together, we’ll deliver for our patients, shareholders and GSK people.

Our Code sets out the commitments GSK and our people make to get ahead together – so we can deliver on our ambition in the right way, bring our culture to life and make GSK an exciting and inspiring place to work.

The Code

In India, we will get #AheadTogether with our three priorities:

Ambitious for patients, to deliver what matters better and faster.
Accountable for impact, with clear ownership and support to succeed.
Do the right thing with integrity and care, because people count on us.

With our new purpose, strategy and culture, we will get ahead of disease in India by continuing our legacy in General Medicines, our leadership in the Vaccines self-pay market and innovative offerings through our Specialty and Oncology portfolio.